Regencell Bioscience Holdings (RGC) Enterprise Value (2020 - 2025)

Regencell Bioscience Holdings' Enterprise Value history runs 6 years deep, the most recent figure standing at -$2.5 million for Q2 2025.

• Quarterly Enterprise Value rose 68.88% year-over-year to -$2.5 million in Q2 2025, while the trailing twelve-month figure through Jun 2024 was -$8.0 million (up 31.4% YoY) and the FY2025 annual result came in at -$2.5 million, up 68.88% from the prior year.
• Enterprise Value was -$2.5 million for Q2 2025 at Regencell Bioscience Holdings, up from -$8.0 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$59413.0 in Q2 2021 and bottomed at -$16.4 million in Q2 2022.
• A 5-year average of -$7.7 million and a median of -$8.0 million in 2024 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2021 — Enterprise Value surged 84.65% — and 2022, when it plunged 27506.1%.
• Regencell Bioscience Holdings' Enterprise Value stood at -$59413.0 in 2021, then plunged by 27506.1% to -$16.4 million in 2022, then grew by 29.24% to -$11.6 million in 2023, then surged by 31.4% to -$8.0 million in 2024, then soared by 68.88% to -$2.5 million in 2025.
• Business Quant data shows RGC's Enterprise Value at -$2.5 million in Q2 2025, -$8.0 million in Q2 2024, and -$11.6 million in Q2 2023.